# Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

* The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”)
* Sapu-003 is an injectable formulation of Everolimus (Afinitor(R)), which aims to offer higher bioavailability and better efficacy than oral versions of the drug
* The trial is conducted alongside partners like the Southern Oncology Clinical Research Unit (“SOCRU”), Ingenū, and Medicilon

 Sapu Nano, which is in the Sapu family of companies, which was through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently revealed the company’s first in-human clinical trial of Sapu-003.

 The announcement occurred at the…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/sapu-nano-reveals-the-initial-in-human-clinical-trial-of-sapu-003-intravenous-everolimus-afinitorr-at-australian-translational-breast-cancer-symposium/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/sapu-nano-unveils-first-human-trial-of-injectable-everolimus-for-breast-cancer/e4a1837294082b816789f02d601d5f3c) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2511/3/rain_Iwj.webp)